NCT06101316View on ClinicalTrials.gov

A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China

PHASE1RecruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

September 19, 2023

Primary Completion Date

October 30, 2023

Study Completion Date

December 29, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

CB06-036

CB06-036 Capsule

Trial Locations (1)

130000

RECRUITING

The First Hospital of Jilin University, Changchun

All Listed Sponsors

lead

Shanghai Zhimeng Biopharma, Inc.

INDUSTRY